ACTRN12624000522516尚未招募Unknown
A Prospective Single-Arm Pilot Study of the Safety, Tolerability and Preliminary Efficacy of Partially Ablative Body Radiotherapy (PABR) for the Palliation of Bulky Tumours
Peter MacCallum Cancer Centre0 个研究点目标入组 30 人开始时间: 2024年4月26日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Histologically or cytologically confirmed non-haematologic malignancy not amenable to curative intent treatment.
- •Must be a candidate for palliative radiotherapy for a tumour size of at least 5cm as measured by clinical examination or radiologic imaging
- •At least one measurable disease tumour lesion as assessed by investigator per RECIST v1.1
- •Not suitable for SABR (stereotactic ablative body radiotherapy) or surgery, or has declined surgery
排除标准
- •Tumours at or within 2cm from spinal cord
- •Prior radiotherapy that overlaps with planned site of intervention within 2 years prior to screening
- •Received concurrent cytotoxic or targeted therapy within 3-4 weeks prior to the fraction of PABR, or concurrent use of these therapies during intervention period
- •Evidence of central necrosis on imaging
研究者
相似试验
已完成
1 期
A clinical trial to study prevention of HPV in HIV-Positive women in IndiaCTRI/2009/091/000298AIDS Malignancy Clinical Trials Consortium150
进行中（未招募）
1 期
A clinical trial for advanced prostatic cancer patients . The study medication will be Leuprolide Mesylate, which will be administered as an injection twice. Both the study doctors and clinical trial participants know which treatment is being administered, there will be only one treatment group.The safety and efficacy of the medicinal product will be tested during the study.Advanced Prostate CarcinomaMedDRA version: 19.0Level: LLTClassification code 10036921Term: Prostate carcinomaSystem Organ Class: 100000004864EUCTR2013-001790-25-DEForesee Pharmaceuticals Co., Ltd.137
进行中（未招募）
1 期
A clinical trial for advanced prostatic cancer patients . The study medication will be Leuprolide Mesylate, which will be administered as an injection twice. Both the study doctors and clinical trial participants know which treatment is being administered, there will be only one treatment group.The safety and efficacy of the medicinal product will be tested during the study.Advanced Prostate CarcinomaMedDRA version: 19.0Level: LLTClassification code 10036921Term: Prostate carcinomaSystem Organ Class: 100000004864EUCTR2013-001790-25-SKForesee Pharmaceuticals Co., Ltd.133
进行中（未招募）
1 期
A clinical trial for advanced prostatic cancer patients . The study medication will be Leuprolide Mesylate, which will be administered as an injection twice. Both the study doctors and clinical trial participants know which treatment is being administered, there will be only one treatment group.The safety and efficacy of the medicinal product will be tested during the study.Advanced Prostate CarcinomaMedDRA version: 19.0Level: LLTClassification code 10036921Term: Prostate carcinomaSystem Organ Class: 100000004864EUCTR2013-001790-25-LTForesee Pharmaceuticals Co., Ltd.133
进行中（未招募）
1 期
A clinical trial for advanced prostatic cancer patients . The study medication will be Leuprolide Mesylate, which will be administered as an injection twice. Both the study doctors and clinical trial participants know which treatment is being administered, there will be only one treatment group.The safety and efficacy of the medicinal product will be tested during the study.Advanced Prostate CarcinomaMedDRA version: 19.0Level: LLTClassification code 10036921Term: Prostate carcinomaSystem Organ Class: 100000004864EUCTR2013-001790-25-ATForesee Pharmaceuticals Co., Ltd.133